3-甲酰吲哚-6-羧酸甲酯 | 133831-28-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-甲酰吲哚-6-羧酸甲酯
• 中文别名: 3-甲酰基吲哚-6-甲酸甲酯；6-甲酸甲酯吲哚-3-甲醛；3-甲酰基吲哚-6-羧酸甲酯
• 英文名称: methyl 3-formyl-6-indolecarboxylate
• 英文别名: 3-Formyl-1H-indole-6-carboxylic acid methyl ester；methyl 3-formyl-1H-indol-6-carboxylate；methyl 3-formyl-1H-indole-6-carboxylate；3-formylindole-6-carboxylic acid methyl ester；methyl 3-formylindole-6-carboxylate；6-methoxycarbonylindol-3-carboxaldehyde
• CAS: 133831-28-4
• 化学式: C₁₁H₉NO₃
• mdl: MFCD00216479
• 分子量: 203.197
• InChiKey: KRDRROJESQUFMJ-UHFFFAOYSA-N

物化性质

• 熔点：
  219-224 °C
• 沸点：
  341.49°C (rough estimate)
• 密度：
  1.2621 (rough estimate)
• 稳定性/保质期：
  遵循规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于阴凉干燥处。

SDS

Name:	Methyl 3-Formylindole-6-Carboxylate 95+% Material Safety Data Sheet
Synonym:	Non
CAS:	133831-28-4

Section 1 - Chemical Product MSDS Name:Methyl 3-Formylindole-6-Carboxylate 95+% Material Safety Data Sheet
Synonym:Non

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
133831-28-4	Methyl 3-Formylindole-6-Carboxylate	95+	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels below recommended exposure limits. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 133831-28-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light purple
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 220.00 - 224.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water: negligible
Specific Gravity/Density:
Molecular Formula: C11H9NO3
Molecular Weight: 203.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures. Stability unknown.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 133831-28-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 3-Formylindole-6-Carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 133831-28-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 133831-28-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 133831-28-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲酰吲哚-6-羧酸甲酯 在 环丁砜 、 sodium hydride 、 sodium cyanoborohydride 、 对甲苯磺酸 、 对甲苯磺酰肼 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 Methyl 3-methyl-1-{3-(phenyl)propyl}-1 H-indole-6-carboxylate
  参考文献：
  名称：

  口服活性吲哚N-氧化物PDE4抑制剂。

  摘要：

  该交流描述了一系列新型有效的磷酸二酯酶（IV）（PDE4）抑制剂的合成以及体外和体内评估。提出的几种化合物在LPS攻击的小鼠（小鼠内毒素血症模型）中具有低纳摩尔IC50抑制PDE4和出色的体内抑制TNF-α水平的活性。介绍了最有效的PDE4抑制剂在SCW关节炎模型中的呕吐研究（狗）和功效。

  DOI：

  10.1016/s0960-894x(98)00572-1
• 作为产物：
  描述：

  吲哚-6-甲酸甲酯 、 乌洛托品 在 水 、 碘 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 150.0 ℃ 、689.49 kPa 条件下， 反应 0.13h， 以77%的产率得到3-甲酰吲哚-6-羧酸甲酯
  参考文献：
  名称：

  连续流动中吲哚的C3甲酰化

  摘要：

  我们已经开发了使用六亚甲基四胺（HMTA）和碘的吲哚连续流动C3甲酰化技术。DMF–H 2 O（1：1，体积/体积）的混合溶剂系统可以完全溶解试剂，并防止流体流动过程中微通道的堵塞。连续流技术可提供最大程度的混合，并具有出色的传热效率。因此，在没有强酸，强碱或金属催化剂的情况下，流化学可加快吲哚的C3甲酰化速率。我们显示，当停留时间低至8分钟时，可以在150°C下获得高产率的C3甲酰化吲哚（高达83％）。

  DOI：

  10.1002/bkcs.12199

文献信息

• Iridium(<scp>iii</scp>) catalyzed regioselective amidation of indoles at the C4-position using weak coordinating groups
  作者：Veeranjaneyulu Lanke、Kandikere Ramaiah Prabhu

  DOI：10.1039/c7cc00763a

  日期：——

  Herein we disclose a simple and short synthetic route for the amidation of indoles at the C4 position by employing an aldehyde as a directing group and Ir(III) as a catalyst. This strategy offers high selectivity for the C4-amidation of unprotected and protected indoles. A simple deprotection of the tosyl group leads to the formation of C4-amino indole derivatives, which are useful synthons for synthesizing

  在几种天然产物和生物活性化合物中经常遇到C4胺化的吲哚支架。本文中，我们公开了通过使用醛作为导向基团和Ir（III）作为催化剂来使吲哚在C4位酰胺化的简单且短的合成路线。该策略为未保护的和被保护的吲哚的C4酰胺化提供了高选择性。甲苯磺酰基的简单脱保护导致形成C 4-氨基吲哚衍生物，其是用于合成调心素家族中的天然产物的有用的合成子。
• [EN] 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE ET COMPOSÉS CORRESPONDANTS UTILISÉS EN TANQUE QUE AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) UTILISÉS POUR LE TRAITEMENT DE, P.EX., DE L'ANGIOGENÈSE IMPLIQUÉE OU DE TROUBLES INFLAMMATOIRES
  申请人：IKENA ONCOLOGY INC

  公开号：WO2021127302A1

  公开（公告）日：2021-06-24

  2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).

  2-(1H-吲哚-3-甲酰基)-噻唑-4-羧酰胺衍生物及相应的咪唑、噁唑和噻吩衍生物以及相关化合物作为芳香烃受体（AHR）激动剂，用于治疗涉及血管生成的疾病，例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症，或炎症性疾病。本说明书揭示了示例化合物的合成和表征以及其药理数据（例如第27至32页和59至219页；示例1至8；化合物1-1至1-97；表1-a、2和3）。
• INDOLE-DERIVED STYRYL DYE COMPRISING AN ALKYLENE LINKER, A DYE COMPOSITION COMPRISING THIS DYE, AND A PROCESS FOR LIGHTENING KERATIN MATERIALS USING THIS DYE
  申请人：Greaves Andrew

  公开号：US20090089939A1

  公开（公告）日：2009-04-09

  The disclosure relates to the dyeing of keratin materials using indole-derived styryl dyes comprising an alkylene linker. Disclosed herein is a dye composition comprising an indole-derived styryl dye comprising an alkylene linker, and a dyeing process with, for example, a lightening effect on keratin materials such as hair, using said composition. Disclosed herein are novel indole-derived styryl dyes comprising an alkylene linker and the uses thereof in lightening keratin materials. This composition makes it possible to obtain a coloring with a lightening effect which can be resistant and visible on dark keratin fibers.

  披露涉及使用含有亚烯基染料和烷基链的吲哚衍生物染料对角蛋白材料进行染色。本公开披露了一种染料组合物，包括一种含有烷基链的吲哚衍生物亚烯基染料，以及使用该组合物对角蛋白材料（如头发）进行漂白效果的染色过程。本公开披露了一种新型含有烷基链的吲哚衍生物亚烯基染料及其在漂白角蛋白材料中的用途。该组合物使得可以获得具有漂白效果的染色，这种效果可以在深色角蛋白纤维上保持并可见。
• Substituted azabicyclic compounds
  申请人：Rhone-Poulenc Rorer Limited

  公开号：US06303600B1

  公开（公告）日：2001-10-16

  This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.

  这项发明涉及公式（I）的某些生理活性化合物 其中 代表一个大约由10到13个环成员组成的双环环系统，其中该环 是一个氮杂环，并且该环 代表一个氮杂芳基环，或者一个可选地卤代苯环； 以及它们的N-氧化物，以及它们的前药，以及公式（I）的化合物及其N-氧化物的药用可接受的盐和溶剂合物，以及它们的前药。这些化合物抑制TNF的产生或生理效应，并抑制环磷酸腺苷磷酸二酯酶。该发明还涉及包括公式（I）的化合物的药物组合物，它们的药用以及其制备方法。
• Quinolines useful in treating cardiovascular disease
  申请人：Collini D. Michael

  公开号：US20050131014A1

  公开（公告）日：2005-06-16

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了式I化合物的用途，它们在治疗或抑制LXR介导的疾病中是有用的。